Response to pazopanib‐based combination regimen in a case of FGFR3 amplified gastric adenocarcinoma-Reference-Cited by-同舟云学术

Response to pazopanib‐based combination regimen in a case of FGFR3 amplified gastric adenocarcinoma

Published:2021-11 Issue:11 Volume:9 Page:
ISSN:2050-0904
Container-title:Clinical Case Reports
language:en
Short-container-title:Clinical Case Reports

Author:

Limaye Sewanti¹,Patil Darshana²,Akolkar Dadasaheb²,Srivastava Navin²,Patil Revati²,Apurwa Sachin²,Patil Sanket²,John Jinumary²,Gosavi Rahul²,Nesargikar Prabhu³,Kumar Prashant⁴⁵⁶,Datta Vineet²,Bose Chirantan²,Raazi Zarrine²,Srinivasan Ajay²^ORCID,Datar Rajan²

Affiliation:

1. Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute Mumbai Maharashtra India

2. Datar Cancer Genetics Nasik Maharashtra India

3. HCG Cancer Centre Bengaluru Karnataka India

4. Institute of Bioinformatics Bengaluru Karnataka India

5. Manipal Academy of Higher Education Manipal Karnataka India

6. Somaiya Institute of Research and ConsultancySomaiya Vidyavihar University Mumbai Maharashtra India

Publisher

Wiley

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ccr3.4986

Reference28 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Gastric cancer: diagnosis and treatment options;Layke JC;Am Fam Physician,2004

3. Gastric carcinoma. A critical review of 243 cases;Olearchyk AS;Am J Gastroenterol,1978

4. Current treatment and recent progress in gastric cancer

5. Stomach cancer: types of treatment. Cancer.net. Accessed September 27 2021.https://www.cancer.net/cancer‐types/stomach‐cancer/types‐treatment

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ponatinib sensitizes myeloma cells to MEK inhibition in the high-risk VQ model;Scientific Reports;2022-06-23

2. FGFR Pathway Inhibition in Gastric Cancer: The Golden Era of an Old Target?;Life;2022-01-07

3. Gemcitabine/pazopanib/pemetrexed;Reactions Weekly;2022-01